Combination Therapy of Cutaneous T Cell Lymphoma with Interferon Alpha-2a and Photochemotherapy

Stadler, R.; Otte, H

doi:10.1007/978-3-642-78771-3_30

Cited by 25 publications

(12 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A further 3 patients suffered local recurrences but repeat treatment maintained the remission. 111 In a series of 25 patients (19 with stage I disease), Rupoli and colleagues reported final response rates of 76% (CR) and 20% (PR). 112 PFS was 82% at 12 months and 62% at 24 months.…”

Section: Denileukin Diftitoxmentioning

confidence: 99%

“…Several relevant studies have already been described. [109][110][111][112] In the trial conducted by Chiarion-Sileni and colleagues, described above, 12 of 63 patients had stage III disease, and the authors noted that CRs were achieved in all disease stages, except in patients with SS. 113 Unfortunately, the response data were not reported by disease stage, or by prior treatment status.…”

Section: Retinoids Plus Puva Thomsen and Colleagues Re-mentioning

confidence: 99%

See 1 more Smart Citation

EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome

Trautinger

Knobler

Willemze

et al. 2006

European Journal of Cancer

391

308

View full text Add to dashboard Cite

Section: Denileukin Diftitoxmentioning

confidence: 99%

Section: Retinoids Plus Puva Thomsen and Colleagues Re-mentioning

confidence: 99%

EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome

Trautinger

Knobler

Willemze

et al. 2006

European Journal of Cancer

391

308

View full text Add to dashboard Cite

“…Bei Mit PUVA kann in 65-80% bei frühen Stadien eine komplette Remission erzielt werden [13]. In Kombination mit Interferon-α werden höhere Ansprechraten erzielt [28], wobei PUVA und Interferon wirksamer erscheinen als Interferon und Acitretin.…”

Section: Puvaunclassified

Standard- und experimentelle Therapie kutaner T-Zell-Lymphome

Beyeler

Dummer

2003

Der Hautarzt

View full text Add to dashboard Cite

Kutane T-Zell-Lymphome (CTCL) stellen eine heterogene Gruppe lymphoproliferativer Neoplasien dar.Nach der Klassifikation der EORTC (European Organization for Research and Treatment of Cancer ) werden die CTCL in 3 Kategorien eingeteilt:▂ indolente mit einer Überlebenszeit von >10 Jahren, ▂ aggressive mit einer Überlebenszeit von <10 Jahren sowie ▂ provisorisch eingeteilte Formen.Zu den indolenten Formen gehören die Mycosis fungoides mit/ohne follikulärer Muzinose, die pagetoide Retikulose, die lymphomatoide Papulose sowie das groß-zellige CD30-positive Lymphom. Die aggressive Gruppe umfasst das Sézary-Syndrom und das großzellige CD30-negative Lymphom, während elastolytisches Lym- Abkürzungen ADO ArbeitsgemeinschaftDermatologische Onkologie CBCL kutane B-Zell-Lymphome CTCL kutane T-Zell-Lymphome EORTC European Organization for Research and Treatment of Cancer FDA Food and Drug Administration IFN Interferon IL Interleukin MHC "major histocompatibility complex" Standard-und experimentelle Therapie kutaner T-Zell-Lymphomeretinoids and photopheresis have been used for years.Bexarotene is a newly registered drug.To achieve better response rates,several new drugs are being evaluated in clinical trails,including imiquimod,denileukon-diftitox,liposomal doxorubicin,adeno-interferon-γ and various combination approaches. AbstractCutaneous T-cell lymphoma represent a heterogeneous group of diseases characterized by skin invasion of monoclonal T-lymphocytes.These cutaneous T-cell lymphomas are divided into 3 groups based on clinical,histological and immunohistological characteristics: Indolent with a survival time of over 10 years,aggressive with a survival time less than 10 years and provisional (EORTC classification).Standard treatments such as PUVA,total skin electron beam, methotrexate,polychemotherapy regimens,

show abstract

“…These treatments are also used in combination with skin-directed regimens in patients with recalcitrant early stage disease . Combination therapies with systemic retinoids and IFN-a do not appear to offer a higher response than IFN-a alone (Olsen, 2003) and appear inferior to IFN-a plus PUVA (Stadler & Otte, 1995). Extracorporeal photopheresis is effective in erythrodermic MF/SS, and bexarotene or IFN-a may enhance efficacy (Dippel et al, 1997;Haley et al, 1999).…”

Section: Prognosis and Treatment Optionsmentioning

confidence: 99%

Clinical manifestations and pathogenesis of cutaneous lymphomas: current status and future directions

et al. 2016

View full text Add to dashboard Cite

SummaryThe primary cutaneous lymphomas are a heterogeneous group of T-, Natural Killer-and B-cell neoplasms with a wide range of clinical and pathological presentations, and with very different prognoses compared to systemic lymphomas. Recent studies have shown that the skin microenvironment, which is composed of various immune cell subsets as well as their spatial distribution and T-cell interactions through different chemokines and cytokines, has an important role in the development and pathogenesis of cutaneous lymphomas and has assisted in the development of novel and more effective immunotherapies. The following review will focus on the major subtypes of primary cutaneous lymphomas, including the clinical and histological patterns, molecular hallmarks, and current and future treatment strategies.

show abstract

Combination Therapy of Cutaneous T Cell Lymphoma with Interferon Alpha-2a and Photochemotherapy

Cited by 25 publications

References 11 publications

EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome

EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome

Standard- und experimentelle Therapie kutaner T-Zell-Lymphome

Clinical manifestations and pathogenesis of cutaneous lymphomas: current status and future directions

Contact Info

Product

Resources

About